欧洲蛋白质体学市场：按细分市场、应用和国家分類的分析和预测（2025-2035 年）

欧洲蛋白质体学市场概览：

欧洲蛋白质体学市场预计将从2024年的69.1亿美元成长到2035年的243.6亿美元，复合年增长率（CAGR）为12.25%。高解析度质谱和次世代定序技术的进步正在扩大蛋白质体学在欧洲的应用，从而实现更深入、更精确的蛋白质分析。该地区对个人化医疗的日益重视进一步推动了市场需求，这主要得益于对发现新的生物标记和改进疾病谱分析的不懈努力。欧盟的大力研究经费、公私合营以及医院、生技公司和学术机构之间的策略联盟正在促进新型蛋白质体学应用的快速发展。欧洲人口老化和慢性病的盛行率上升，促使人们更需要改善诊断和早期检测技术。这些因素共同推动蛋白质体学成为临床创新的基础组成部分，并成为该地区生命科学研究生态系统的关键驱动力。

市场区隔:

细分 1：按服务类别

• 样品製备
• 蛋白质体学技术
  • 试剂和耗材
  • 装置
  • 软体
• 蛋白质体学服务

细分 2：按应用

• 生物标记的发现与检验
• 蛋白质体分析和图谱绘製
• 药物发现与开发
• 伴随诊断
• 蛋白质-蛋白质相互作用

细分3：按地区

• 欧洲

欧洲蛋白质体学市场趋势、驱动因素与挑战：

趋势：

• 从发现性蛋白质体学到临床和转化应用的转变正在加速，尤其是在肿瘤学和神经病学领域。
• 快速采用先进的质谱、单细胞蛋白质体学和高通量蛋白质分析平台
• 拓展基于蛋白质体学的诊断方法和伴随生物标记的开发，以支持精准医疗。
• 加强大学、医院、生物技术公司和欧盟资助的研究网络之间的合作
• 人们对整合基因组学、转录组学和蛋白​​质组学的多体学工作流程的兴趣日益浓厚

司机：

• 欧盟资助的强有力计画和国家研究津贴将加速蛋白质体学创新
• 对早期检测工具、疾病分层和个人化治疗方案的需求很高
• 先进的医疗基础设施和数位健康解决方案的广泛应用
• 生技公司、製药公司和合约研究组织（CRO）加强对生物标记发现和治疗开发的研发投入
• 更加重视标准化、品管和检验的临床蛋白质体学流程

任务：

• 严格的法律规范，包括遵守体外诊断医疗器材法规 (IVDR)，会增加成本并延长产品上市时间。
• 欧洲多个地区缺乏熟练的蛋白质体学专家和生物资讯学家
• 精密设备的昂贵成本及其维护费用限制了其在小规模研究实验室的应用。
• 整合跨多体学平台和医疗保健系统的片段化数据
• 基于蛋白质体学的诊断技术的商业化进程缓慢，且有报销障碍。

本报告考察了欧洲蛋白质体学市场，并总结了关键趋势、市场影响因素分析、法律制度、技术和专利分析、市场规模趋势和预测、按各个细分市场、地区/主要国家进行的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

范围和定义

第一章 市场：产业展望

• 市场概览与生态系统
• 与其他体学相比，蛋白质体学的比较优势和劣势
• 供应链分析
• 市场动态
  • 趋势、驱动因素、挑战和机会：评估当前和未来的影响
• 趋势
  • 加速端到端蛋白质体学工作流程的自动化
  • 拓展蛋白质体学研究以识别疾病生物标记
  • 公司间的众多合作
• 市场动态
  • 市场驱动因素
  • 市场挑战
  • 商业策略
  • 企业策略
  • 市场机会
• 监管状态/合规性
  • 欧洲
• 专利分析
  • 专利分析（按年份）
  • 专利分析（按国家）

第二章 区域

• 区域摘要
• 欧洲
  • 区域概览
  • 市场成长驱动因素
  • 市场问题
  • 按供应类别
  • 透过使用
  • 按国家/地区

第三章 市场：竞争基准化分析与公司概况

• 公司简介
  • DiaSorin SPA

第四章调查方法

This report can be delivered in 2 working days.

Introduction to Europe Proteomics Market

The Europe proteomics market is projected to reach $24.36 billion by 2035 from $6.91 billion in 2024, growing at a CAGR of 12.25% during the forecast period 2025-2035. Advances in high-resolution mass spectrometry and next-generation sequencing technologies are increasing proteomics usage in Europe, allowing for deeper and more precise protein analysis. Demand is being further increased by the region's increasing emphasis on personalized healthcare, which is being fueled by initiatives to find new biomarkers and improve disease-profiling skills. The development of new proteomic applications is developing quickly thanks to strong EU-backed research funding, public-private partnerships, and strategic alliances between hospitals, biotech companies, and academic institutions. Improved diagnostics and early-detection technologies are becoming more and more necessary as Europe's population ages and the prevalence of chronic illnesses rises. When taken as a whole, these factors are establishing proteomics as a fundamental component of clinical innovation and a major force behind the ecosystem of life-science research in the area.

Market Introduction

Advances in high-resolution mass spectrometry and next-generation sequencing technologies are increasing proteomics usage in Europe, allowing for deeper and more precise protein analysis. Demand is being further increased by the region's increasing emphasis on personalized healthcare, which is being fueled by initiatives to find new biomarkers and improve disease-profiling skills. The development of new proteomic applications is developing quickly thanks to strong EU-backed research funding, public-private partnerships, and strategic alliances between hospitals, biotech companies, and academic institutions. Improved diagnostics and early-detection technologies are becoming more and more necessary as Europe's population ages and the prevalence of chronic illnesses rises. When taken as a whole, these factors are establishing proteomics as a fundamental component of clinical innovation and a major force behind the ecosystem of life-science research in the area.

Across the region, the push toward personalised healthcare is accelerating the adoption of proteomics in oncology, neurology, cardiology, and chronic disease management. The development of next-generation proteomic applications is being accelerated by national innovation awards, EU-funded research initiatives, and cross-border partnerships between hospitals, biotech firms, academic institutions, and CROs. This robust financing ecosystem promotes standardization, data interoperability, and clinical validation of proteomic procedures in addition to supporting scientific innovation.

The need for early detection techniques, predictive biomarkers, and more focused treatment approaches is growing as Europe's population ages and the prevalence of chronic diseases rises. Proteomics is therefore becoming recognized as a key facilitator of better patient outcomes and healthcare effectiveness. Europe is well-positioned to spearhead the next generation of clinical and technological developments in proteomics thanks to its strong infrastructure, quality-focused regulations, and developed research environment.

Market Segmentation:

Segmentation 1: By Offering

• Sample Preparation
• Proteomics Technologies
  • Reagents and Consumables
  • Instruments
  • Software
• Proteomics Services

Segmentation 2: By Application

• Biomarker Discovery and Validation
• Proteome Profiling and Mapping
• Drug Discovery and Development
• Companion Diagnostics
• Protein-Protein Interactions

Segmentation 3: By Region

• Europe

Europe Proteomics Market Trends, Drivers and Challenges

Trends

• Growing shift from discovery proteomics to clinical and translational applications, especially in oncology and neurology.
• Rapid adoption of advanced mass spectrometry, single-cell proteomics, and high-throughput protein analysis platforms.
• Expansion of proteomics-based diagnostics and companion biomarker development supporting precision medicine.
• Increasing collaborations among universities, hospitals, biotech firms, and EU-funded research networks.
• Rising focus on integrated multi-omics workflows combining genomics, transcriptomics, and proteomics.

Drivers

• Strong EU funding programs and national research grants accelerating proteomics innovation.
• High demand for early-detection tools, disease stratification, and personalized treatment pathways.
• Advanced healthcare infrastructure and widespread adoption of digital health solutions.
• Growing R&D investment from biotech, pharma, and CROs in biomarker discovery and therapeutic development.
• Increased emphasis on standardization, quality control, and validated clinical proteomics pipelines.

Challenges

• Stringent regulatory frameworks, including IVDR compliance, increasing cost and time to market.
• Shortage of skilled proteomics experts and bioinformaticians across several European regions.
• High cost of advanced instrumentation and maintenance, limiting adoption in smaller labs.
• Fragmented data integration across multi-omics platforms and healthcare systems.
• Slow commercialization and reimbursement barriers for proteomics-based diagnostics.

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in the Europe proteomics market. It guides R&D investment strategies, technology adoption, and pipeline optimization, helping companies prioritize initiatives that accelerate biomarker discovery, disease diagnostics, and therapeutic development. By highlighting emerging technologies, strategic collaborations, and platform scalability, this report helps organizations strengthen their competitive positioning and capitalize on the rapid expansion of proteomics across research, clinical, and pharmaceutical applications.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the proteomics ecosystem.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Comparative Advantages and Disadvantages of Proteomics Over Other Omics
• 1.3 Supply Chain Analysis
• 1.4 Market Dynamics
  • 1.4.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
• 1.5 Trends
  • 1.5.1 Increasing Automation for End-to-End Proteomics Workflow
  • 1.5.2 Growing Proteomics Research to Identify Disease Biomarkers
  • 1.5.3 Significant Number of Collaborations among Market Players
• 1.6 Market Dynamics
  • 1.6.1 Market Drivers
    • 1.6.1.1 Rising Prevalence of Chronic Diseases
    • 1.6.1.2 Continuous Technological Advancements
    • 1.6.1.3 Increasing Demand for Personalized Medicine
  • 1.6.2 Market Challenges
    • 1.6.2.1 High Costs of Acquisition Hindering the Adoption of Proteomics Technologies
    • 1.6.2.2 Shortage of Skilled Professionals
  • 1.6.3 Business Strategies
    • 1.6.3.1 Key Product Launch/Expansion
  • 1.6.4 Corporate Strategies
    • 1.6.4.1 Key Partnerships
    • 1.6.4.2 Key Funding and Grants
    • 1.6.4.3 Key Merger and Acquisitions
  • 1.6.5 Market Opportunities
    • 1.6.5.1 Expanding Proteomics Market in Emerging Regions through Affordable Technologies
• 1.7 Regulatory Landscape/Compliance
  • 1.7.1 Europe
    • 1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices
      • 1.7.1.1.1 EU Medical Device Regulation
      • 1.7.1.1.2 EU In Vitro Diagnostic Regulation
      • 1.7.1.1.3 Regulatory Requirements for Clinical Proteomics Labs in the EU
• 1.8 Patent Analysis
  • 1.8.1 Patent Analysis (by Year)
  • 1.8.2 Patent Analysis (by Country)

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 By Offering
    • 2.2.4.1 By Proteomics Technologies
  • 2.2.5 By Application
  • 2.2.6 By Country
    • 2.2.6.1 U.K.
      • 2.2.6.1.1 By Offering
      • 2.2.6.1.2 By Application
    • 2.2.6.2 Germany
      • 2.2.6.2.1 By Offering
      • 2.2.6.2.2 By Application
    • 2.2.6.3 France
      • 2.2.6.3.1 By Offering
      • 2.2.6.3.2 By Application
    • 2.2.6.4 Italy
      • 2.2.6.4.1 By Offering
      • 2.2.6.4.2 By Application
    • 2.2.6.5 Spain
      • 2.2.6.5.1 By Offering
      • 2.2.6.5.2 By Application
    • 2.2.6.6 Rest-of-Europe
      • 2.2.6.6.1 By Offering
      • 2.2.6.6.2 By Application

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Company Profile
  • 3.1.1 DiaSorin S.P.A.
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products/Product Portfolio
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Target Customers
    • 3.1.1.5 Key Personal
    • 3.1.1.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Proteomics Market (by Scenario), $Billion, 2024, 2030, and 2035
• Figure 2: Proteomics Market, $Billion, 2024 and 2035
• Figure 3: Europe Proteomics Market (by Offering), $Billion, 2024, 2030, and 2035
• Figure 4: Europe Proteomics Market (by Application), $Billion, 2024, 2030, and 2035
• Figure 5: Europe Proteomics Market Segmentation
• Figure 6: Ecosystem Europe Proteomics Market
• Figure 7: Supply Chain and Risks within the Supply Chain
• Figure 8: Proteomics Market, Patent Analysis (by Year), January 2021-December 2024
• Figure 9: Proteomics Market, Patent Analysis (by Country), January 2021-December 2024
• Figure 10: U.K. Proteomics Market, $Billion, 2024-2035
• Figure 11: Germany Proteomics Market, $Billion, 2024-2035
• Figure 12: France Proteomics Market, $Billion, 2024-2035
• Figure 13: Italy Proteomics Market, $Billion, 2024-2035
• Figure 14: Spain Proteomics Market, $Billion, 2024-2035
• Figure 15: Rest-of-Europe Proteomics Market, $Billion, 2024-2035
• Figure 16: Data Triangulation
• Figure 17: Top-Down and Bottom-Up Approach
• Figure 18: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Opportunities across Regions
• Table 3: Partnerships and Collaborations in the Europe Proteomics Market
• Table 4: Proteomics Market (by Region), $Billion, 2024-2035
• Table 5: Europe Proteomics Market (by Offering), $Billion, 2024-2035
• Table 6: Europe Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 7: Europe Proteomics Market (by Application), $Billion, 2024-2035
• Table 8: U.K. Proteomics Market (by Offering), $Billion, 2024-2035
• Table 9: U.K. Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 10: U.K. Proteomics Market (by Application), $Billion, 2024-2035
• Table 11: Germany Proteomics Market (by Offering), $Billion, 2024-2035
• Table 12: Germany Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 13: Germany Proteomics Market (by Application), $Billion, 2024-2035
• Table 14: France Proteomics Market (by Offering), $Billion, 2024-2035
• Table 15: France Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 16: France Proteomics Market (by Application), $Billion, 2024-2035
• Table 17: Italy Proteomics Market (by Offering), $Billion, 2024-2035
• Table 18: Italy Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 19: Italy Proteomics Market (by Application), $Billion, 2024-2035
• Table 20: Spain Proteomics Market (by Offering), $Billion, 2024-2035
• Table 21: Spain Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 22: Spain Proteomics Market (by Application), $Billion, 2024-2035
• Table 23: Rest-of-Europe Proteomics Market (by Offering), $Billion, 2024-2035
• Table 24: Rest-of-Europe Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 25: Rest-of-Europe Proteomics Market (by Application), $Billion, 2024-2035